| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 14.677 | 26.111 | 25.382 | 31.410 | 30.160 | 30.879 | 52.398 | 58.756 | 54.613 | 59.888 |
| Total Income - EUR | 14.677 | 26.111 | 25.382 | 31.410 | 30.160 | 30.879 | 52.398 | 58.756 | 54.613 | 59.888 |
| Total Expenses - EUR | 16.425 | 24.756 | 24.424 | 28.602 | 27.535 | 24.346 | 45.838 | 51.074 | 51.052 | 61.091 |
| Gross Profit/Loss - EUR | -1.748 | 1.355 | 958 | 2.809 | 2.625 | 6.533 | 6.560 | 7.682 | 3.561 | -1.203 |
| Net Profit/Loss - EUR | -2.188 | 954 | 704 | 2.494 | 2.323 | 5.749 | 6.039 | 7.107 | 3.096 | -1.714 |
| Employees | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 |
Check the financial reports for the company - Parmicrin Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.875 |
| Current Assets | 19.536 | 24.134 | 28.577 | 27.914 | 27.722 | 33.037 | 44.033 | 53.839 | 57.998 | 61.966 |
| Inventories | 15.436 | 20.195 | 25.195 | 25.778 | 27.278 | 31.794 | 40.967 | 52.537 | 55.403 | 60.038 |
| Receivables | 3.208 | 2.847 | 2.978 | 1.434 | 246 | 0 | 0 | 0 | 0 | 0 |
| Cash | 892 | 1.092 | 404 | 702 | 198 | 1.243 | 3.065 | 1.302 | 2.595 | 1.928 |
| Shareholders Funds | -19.683 | -18.528 | -17.510 | -14.816 | -12.206 | -6.225 | -48 | 7.060 | 10.135 | 8.365 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 39.219 | 42.662 | 46.087 | 42.730 | 39.927 | 39.262 | 44.081 | 46.778 | 47.863 | 55.477 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4711 - 4711" | |||||||||
| CAEN Financial Year |
4649
|
|||||||||
Comments - Parmicrin Srl